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Prevalence and 1-year incidence of frailty among women with and without HIV in the Women’s Interagency
HIV Study
A previous cross-sectional analysis of 2028 women in the
Women’s Interagency HIV Study (WIHS), who were on
average 39 years old, found a frailty prevalence of 17% and
10% in women with or at risk for HIV, respectively [1]. To
our knowledge, the only two longitudinal studies of
frailty among people with HIV were conducted in the
Multicenter AIDS Cohort Study (MACS), which
includes only men [2,3]. Data on the distribution of
frailty components are limited, and have not been
reported for HIV-seropositive people in the United States
[4–7].
The current analysis included data from eight WIHS sites
located in Brooklyn, New York; San Francisco,
California; Chicago, Illinois; Washington, DC; Atlanta,
Georgia; Chapel Hill, North Carolina; Miami, Florida;
and Birmingham, Alabama/Jackson, Mississippi [8–10].
Institutional review board approval was obtained at each
site and written informed consent was obtained from all
women. The study sample included 1404 women aged at
least 40 years old who had at least one frailty assessment
between 1 October 2015 and 30 September 2017. Of the
1404 women, 424 had frailty assessments taken at both
baseline and approximately a 1-year period of follow-up;
46 women were excluded because of frail status at baseline
and 378 women were included in analyses estimating the
1-year risk of frailty.
Since 1 October 2015, the WIHS protocol has included
the measurement of frailty components and determined
frailty status among women aged at least 40 years old. The
Fried Frailty Index, a tool validated in the Cardiovascular
Health Study, was used to operationalize the frailty
phenotype based on five components: weakness, slow-
ness, unintentional weight loss, low activity, and
exhaustion [4]. Frail, prefrail, and robust statuses were
defined as exceeding the component-specific threshold
for at least three frailty components, two frailty
components, and one or less frailty component,
respectively [4]. We used the cut-off points for walking
speed and grip strength validated by Fried, unlike
previous analyses, which used the highest and lowest
quintiles of the distributions from their HIV-seronegative
populations [1–4].
The median age was 52 years [interquartile range (IQR):
47–57] for both women with HIV (n¼ 1025) and
without HIV (n¼ 379). Most women were black non-
Hispanic [75% (n¼ 1055)], had at least a high school
education [70% (n¼ 977)], and had an annual household
income $18 000 or less [63% (n¼ 876)]. The prevalence
of current smoking [47% (n¼ 177); 38% (n¼ 392)],
weekly alcohol consumption greater than seven drinks
[19% (n¼ 73); 6% (n¼ 65)], and other substance use [34%
(n¼ 128); 25% (n¼ 252)] was higher among women
without HIV than among women with HIV. Among
women with HIV, 71% (n¼ 732) had an undetectable
viral load.
The overall prevalence of frailty was 11.5% (n¼ 161/
1404); 10.0% (n¼ 103/1025) among women with HIV
and 15.3% among women without HIV (n¼ 58/379).
Frailty prevalence was higher for women without HIV
compared with women with HIV for all age groups
except 55–59 years (Fig. 1a). Low physical activity was
the most frequently occurring frailty component
(Fig. 1b). The prevalence of frailty components was
similar for women with and without HIV, except that it
was more common for women with HIV to report
unintentional weight loss and for women without HIV to
meet the definition for weakness for each frailty category
(Fig. 1b). The most common combinations of frailty
components were similar in women with and without
HIVand included low physical activity and exhaustion for
prefrail women [67% (n¼ 252)], and these components in
combination with one other component for frail women
[68% (n¼ 110)]. The prevalence of current smoking
[41% (n¼ 41); 41% (n¼ 113)], weekly alcohol consump-
tion greater than seven drinks [18% (n¼ 18); 9%
(n¼ 26)], and other substance use [31% (n¼ 31); 22%
(n¼ 60)] was more balanced between women without
HIV (n¼ 101) and women with HIV (n¼ 277) in the risk
sample compared with the prevalence sample. The overall
1-year risk of frailty was 6.6% (95% confidence interval
4.1–9.1) and similar for women with [6.5% (n¼ 18)] and
without HIV [6.9% (n¼ 7)].
Previous general population studies suggest that frailty is
associated with older age, female sex, minority race/
ethnicity, lower socioeconomic status, geographic loca-
tion, comorbidities, poor nutrition, smoking, and
possibly alcohol consumption [1,4,11–14]. To ensure
comparability to HIV-seropositive women, the WIHS
preferentially recruited HIV-seronegative women with
characteristics that are associated with an increased risk of
HIV infection, such as injection drug use [9]. Several of
these risk characteristics are highly prevalent in the WIHS
population [10]; some were more prevalent among
women without HIV in our sample. Our findings suggest
that social and behavioral risk factors could play a pivotal
role in frailty occurrence among HIV-seropositive
women with or those who are seronegative but at risk
for HIV infection. Future studies should investigate
modifiable risk factors to reduce the burden of frailty
among women with and without HIV, who are
vulnerable to frailty at ages even younger than 65 years.
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